FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006013310> ?p ?o ?g. }

• W2006013310 endingPage "292" @default.
• W2006013310 startingPage "285" @default.
• W2006013310 abstract "A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy.BackgroundDiabetic nephropathy progresses relentlessly to end-stage renal disease (ESRD). Animal experiments have found that peroxisome proliferator activated receptor-γ (PPAR-γ)-based therapy can have a glucose independent effect on renal protection. We hypothesized that PPAR-γ-based antidiabetic therapy would result in greater reduction in proteinuria compared to sulfonylurea-based therapy.MethodsIn 44 patients with overt diabetic nephropathy, an open-label, blinded end point trial was conducted in which subjects were randomized to either pioglitazone or glipizide to achieve similar glucose control. Proteinuria was assessed by two collections of 24-hour urine samples each month for 4 months.ResultsThe glipizide group had an adjusted mean increase in proteinuria of 6.1% (95% CI -11.7%, 23.8%), whereas the pioglitazone group had a reduction of 7.2% (95% CI -24.9%, 10.6%). The adjusted reduction with pioglitazone of 13.2% (95% CI -38.4%, 11.9%) was not statistically significant (P = 0.294). Baseline proteinuria, diastolic ambulatory blood pressure, and serum albumin concentration were independent predictors of reduction in proteinuria. The frequency and patterns of adverse events were similar in the two groups.ConclusionIn patients with advanced diabetic nephropathy, we found no reduction in proteinuria over 4 months. These data are useful to design larger studies with longer duration of follow-up to demonstrate renal protection of PPAR-γ agonists. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Diabetic nephropathy progresses relentlessly to end-stage renal disease (ESRD). Animal experiments have found that peroxisome proliferator activated receptor-γ (PPAR-γ)-based therapy can have a glucose independent effect on renal protection. We hypothesized that PPAR-γ-based antidiabetic therapy would result in greater reduction in proteinuria compared to sulfonylurea-based therapy. In 44 patients with overt diabetic nephropathy, an open-label, blinded end point trial was conducted in which subjects were randomized to either pioglitazone or glipizide to achieve similar glucose control. Proteinuria was assessed by two collections of 24-hour urine samples each month for 4 months. The glipizide group had an adjusted mean increase in proteinuria of 6.1% (95% CI -11.7%, 23.8%), whereas the pioglitazone group had a reduction of 7.2% (95% CI -24.9%, 10.6%). The adjusted reduction with pioglitazone of 13.2% (95% CI -38.4%, 11.9%) was not statistically significant (P = 0.294). Baseline proteinuria, diastolic ambulatory blood pressure, and serum albumin concentration were independent predictors of reduction in proteinuria. The frequency and patterns of adverse events were similar in the two groups. In patients with advanced diabetic nephropathy, we found no reduction in proteinuria over 4 months. These data are useful to design larger studies with longer duration of follow-up to demonstrate renal protection of PPAR-γ agonists." @default.
• W2006013310 created "2016-06-24" @default.
• W2006013310 creator A5014629621 @default.
• W2006013310 creator A5015233743 @default.
• W2006013310 creator A5027326677 @default.
• W2006013310 creator A5031469609 @default.
• W2006013310 creator A5037672300 @default.
• W2006013310 creator A5045518901 @default.
• W2006013310 creator A5073198968 @default.
• W2006013310 creator A5089305017 @default.
• W2006013310 date "2005-07-01" @default.
• W2006013310 modified "2023-09-26" @default.
• W2006013310 title "A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy" @default.
• W2006013310 cites W1963713924 @default.
• W2006013310 cites W1963864987 @default.
• W2006013310 cites W1980198526 @default.
• W2006013310 cites W1984636592 @default.
• W2006013310 cites W1986924251 @default.
• W2006013310 cites W1997223215 @default.
• W2006013310 cites W2007437966 @default.
• W2006013310 cites W2009381728 @default.
• W2006013310 cites W2014877159 @default.
• W2006013310 cites W2016190389 @default.
• W2006013310 cites W2017268330 @default.
• W2006013310 cites W2018160773 @default.
• W2006013310 cites W2026397009 @default.
• W2006013310 cites W2033073066 @default.
• W2006013310 cites W2044773944 @default.
• W2006013310 cites W2048187349 @default.
• W2006013310 cites W2049227087 @default.
• W2006013310 cites W2051159435 @default.
• W2006013310 cites W2055008347 @default.
• W2006013310 cites W2056726092 @default.
• W2006013310 cites W2056976690 @default.
• W2006013310 cites W2071879339 @default.
• W2006013310 cites W2080836692 @default.
• W2006013310 cites W2082460839 @default.
• W2006013310 cites W2083008696 @default.
• W2006013310 cites W2087207277 @default.
• W2006013310 cites W2089316009 @default.
• W2006013310 cites W2096875294 @default.
• W2006013310 cites W2113601694 @default.
• W2006013310 cites W2114098559 @default.
• W2006013310 cites W2117622300 @default.
• W2006013310 cites W2133690273 @default.
• W2006013310 cites W2134815606 @default.
• W2006013310 cites W2137936645 @default.
• W2006013310 cites W2139074604 @default.
• W2006013310 cites W2163839619 @default.
• W2006013310 cites W2165199383 @default.
• W2006013310 cites W2615684303 @default.
• W2006013310 cites W3156148333 @default.
• W2006013310 cites W3198570063 @default.
• W2006013310 cites W4242344507 @default.
• W2006013310 cites W4246362004 @default.
• W2006013310 cites W4249622238 @default.
• W2006013310 doi "https://doi.org/10.1111/j.1523-1755.2005.00416.x" @default.
• W2006013310 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15954919" @default.
• W2006013310 hasPublicationYear "2005" @default.
• W2006013310 type Work @default.
• W2006013310 sameAs 2006013310 @default.
• W2006013310 citedByCount "67" @default.
• W2006013310 countsByYear W20060133102012 @default.
• W2006013310 countsByYear W20060133102013 @default.
• W2006013310 countsByYear W20060133102014 @default.
• W2006013310 countsByYear W20060133102015 @default.
• W2006013310 countsByYear W20060133102016 @default.
• W2006013310 countsByYear W20060133102017 @default.
• W2006013310 countsByYear W20060133102018 @default.
• W2006013310 countsByYear W20060133102019 @default.
• W2006013310 countsByYear W20060133102020 @default.
• W2006013310 countsByYear W20060133102021 @default.
• W2006013310 countsByYear W20060133102022 @default.
• W2006013310 countsByYear W20060133102023 @default.
• W2006013310 crossrefType "journal-article" @default.
• W2006013310 hasAuthorship W2006013310A5014629621 @default.
• W2006013310 hasAuthorship W2006013310A5015233743 @default.
• W2006013310 hasAuthorship W2006013310A5027326677 @default.
• W2006013310 hasAuthorship W2006013310A5031469609 @default.
• W2006013310 hasAuthorship W2006013310A5037672300 @default.
• W2006013310 hasAuthorship W2006013310A5045518901 @default.
• W2006013310 hasAuthorship W2006013310A5073198968 @default.
• W2006013310 hasAuthorship W2006013310A5089305017 @default.
• W2006013310 hasBestOaLocation W20060133101 @default.
• W2006013310 hasConcept C126322002 @default.
• W2006013310 hasConcept C126894567 @default.
• W2006013310 hasConcept C134018914 @default.
• W2006013310 hasConcept C2776174234 @default.
• W2006013310 hasConcept C2777180221 @default.
• W2006013310 hasConcept C2778384471 @default.
• W2006013310 hasConcept C2778653478 @default.
• W2006013310 hasConcept C2779561371 @default.
• W2006013310 hasConcept C2779922275 @default.
• W2006013310 hasConcept C2780091579 @default.
• W2006013310 hasConcept C2781184683 @default.
• W2006013310 hasConcept C555293320 @default.
• W2006013310 hasConcept C71924100 @default.
• W2006013310 hasConceptScore W2006013310C126322002 @default.

• next